Effect of zidovudine on blood composition of the pregnant and fetal baboon - 10/09/11
Abstract |
OBJECTIVE: Our purpose was to assess the effect of intravenous zidovudine on placental function and fetal well-being.
STUDY DESIGN: Eighteen chronically instrumented third-trimester pregnant baboons and their fetuses were studied after 4- to 48-hour infusions of zidovudine to 14 mothers (0.8 to 2.0 mg/kg/hr) and 6 fetuses (0.2 to 0.22 mg/kg/hr of maternal weight). Fetal and maternal pH and blood gases, hematocrit, blood cell counts, clinical chemistries, electrolytes, and hormones were measured before and after the infusions.
RESULTS: In both mother and fetus no significant differences were found between values in the control periods and those after infusions of zidovudine in any of the index values measured.
CONCLUSION: Administration of zidovudine from 4 to 48 hours in the baboon was associated with no significant change in any biochemical index values in the mother or fetus. Thus comparable exposure of the human fetus to zidovudine during labor is not expected to affect these index values of placental function and fetal well-being. (Am J Obstet Gynecol 1997;176:1095-8.)
Le texte complet de cet article est disponible en PDF.Keywords : Fetus, baboon, zidovudine, clinical chemistries, hematologic index values
Plan
 | From the Departments of Anesthesiology,a Pediatrics,b and Psychiatry,c Columbia College of Physicians and Surgeons, Columbia University, and the Department of Obstetrics and Gynecology, St. Luke's Roosevelt Hospital Center.d |
| Supported by National Institute of Allergy and Infectious Diseases grant No. AI32314, National Institute of Child Health and Human Development grant No. HD13063, and the Aaron Diamond Foundation. |
 | Reprint requests: Salha S. Daniel, PhD, Columbia College of Physicians and Surgeons, 630 W. 168th St., New York, NY 10032. |
| 0002-9378/97 $5.00 + 0 6/1/80627 |
Vol 176 - N° 5
P. 1095-1098 - mai 1997 Retour au numéro
Article précédent
- Transdermal nicotine replacement in pregnancy: Maternal pharmacokinetics and fetal effects
- Lydia N. Wright, John M. Thorp, Jeffrey A. Kuller, Robert P. Shrewsburyb, Cande Ananth, Katherine Hartmann
- Do low-risk pregnant women with antiphospholipid antibodies need to be treated?
- Susan Cowchock, E.Albert Reece, For the Organizing Group of the Antiphospholipid Antibody Treatment Trial
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?